AlphaGen
Access AlphaGen
Company Narratives

GlaxoSmithKline Pakistan H1 2026: Stronger Margins Meet a Heavier Tax Drag

GSK Pakistan’s H1 2026 operating performance improved on stronger margins, but Q2 PAT slipped as tax and administrative costs rose.

Sep 16, 2026

Company Name: GlaxoSmithKline Pakistan Limited

Ticker: GLAXO

Reporting period: Quarter and half year ended June 30, 2026. The half-year condensed interim financial statements are unaudited but were subject to a limited-scope review by the statutory auditor; the three-month June-quarter figures themselves were not reviewed. Official H1 2026 report.

Verdict

GSK Pakistan’s H1 2026 result shows a business whose underlying profitability is still improving even though the June quarter’s headline earnings softened. Q2 revenue slipped 1.6% year on year to Rs14.49 billion, but gross profit rose 3.0% and gross margin widened by about 1.7 percentage points to 38.2%. Operating profit also edged higher. Profit after tax, however, fell 4.8% to Rs1.97 billion because the tax charge rose materially and administrative expenses increased. The half-year picture is stronger: sales rose 4.0%, gross profit 11.4%, operating profit 10.1% and PAT 9.2%. Management attributes underlying sales growth to pricing and tender business, and the margin uplift to price increases following deregulation of non-essential medicines plus profitability and sustainability measures. The key question for the next cycle is whether GSK can preserve this margin improvement while converting a large inventory build into sales and absorbing a heavier tax burden. Official H1 2026 report.

AlphaGen model readings

Alpha QoQ Score: 12.18

TTM Performance Score: 96

3Y Business Perf Score: 95.19

Sector Leadership Score: 55.3643

These four readings are AlphaGen model outputs, not company-reported figures. They are shown separately from the issuer’s public financial statements and do not constitute investment advice.

Results at a glance

  • Q2 2026 revenue was Rs14.491 billion versus Rs14.721 billion, down 1.6% year on year. Gross profit increased to Rs5.539 billion from Rs5.377 billion, lifting gross margin to 38.22% from 36.52%. Official statements.
  • Q2 operating profit rose 1.5% to Rs3.650 billion and operating margin improved to 25.19% from 24.42%. Profit before tax increased 4.3% to Rs3.644 billion, but PAT declined 4.8% to Rs1.970 billion and EPS eased to Rs6.19 from Rs6.50. Official statements.
  • For H1 2026, revenue increased 4.0% to Rs31.519 billion, gross profit rose 11.4% to Rs11.922 billion, operating profit increased 10.1% to Rs7.961 billion and PAT rose 9.2% to Rs4.581 billion. H1 EPS improved to Rs14.38 from Rs13.17. Official statements.
  • The Board approved an interim cash dividend of Rs7 per share for the period, compared with Rs5 per share for the comparable 2025 period. Subsequent-events note.
  • Cash generated from operations rose 24.0% to Rs8.664 billion, although net operating cash flow increased only 3.1% to Rs3.880 billion after much higher income-tax payments. Inventory increased 20.7% from December 2025 to Rs15.416 billion. Official cash flow and balance sheet.

What improved

The most important improvement is gross profitability. In Q2, revenue was slightly lower, yet cost of sales fell 4.2%, allowing gross profit to grow 3.0%. That moved gross margin to 38.2% from 36.5%. On a half-year basis, gross margin reached 37.8% versus 35.3%, an expansion of roughly 2.5 percentage points. Management directly links the half-year improvement to price increases through deregulation of non-essential products and to profitability and sustainability initiatives. Directors’ review and statements.

The pricing backdrop is not merely a company narrative. DRAP’s own documentation says the Government amended the Drug Pricing Policy in February 2024 to deregulate prices of non-essential medicines outside the National Essential Medicines List. That policy change created more room for manufacturers to recover inflation and input-cost pressure in eligible products. GSK’s current margin improvement is therefore consistent with a structural pricing change already visible in its 2025 results, although individual product pricing remains subject to the regulatory framework and the company says some hardship and threshold cases remain pending. DRAP deregulation background. GSK H1 commentary.

The H1 result extends rather than creates the margin recovery visible in 2025. GSK’s 2025 annual report attributed that year’s profitability improvement to price increases through deregulation of non-essential products and to profitability and sustainability measures. H1 2026 therefore looks like a continuation of an established operating recovery rather than a single-quarter anomaly; the new wrinkle is that Q2 margins still improved even as quarterly revenue slipped. GSK Annual Report 2025.

Operating profit also held up better than revenue in Q2. Selling, marketing and distribution expense fell 5.2% year on year to Rs1.443 billion, while other operating expenses were broadly stable. Administrative expense rose sharply, but the stronger gross margin and lower selling cost were enough to keep operating profit growing. For H1, operating margin improved to about 25.3% from 23.9%, showing that the gross-margin benefit was not fully consumed by operating expenses. Official statements.

Finance leakage has also reduced dramatically. Q2 financial charges fell to just Rs6.2 million from Rs100.3 million, while H1 charges fell to Rs29.5 million from Rs214.4 million. The balance sheet shows no conventional borrowing line; financial liabilities are mainly lease liabilities. On that basis, it is reasonable to infer that earnings are less sensitive to domestic interest rates than those of a heavily leveraged manufacturer. Official statements.

What weakened / needs attention

The clearest weakness is that Q2 PAT moved in the opposite direction from operating profit. Income tax expense rose 17.3% to Rs1.674 billion even though pre-tax profit increased only 4.3%. The implied Q2 effective tax rate rose to about 45.9% from 40.8%. That tax drag more than offset the operating and finance-cost improvement and pushed net margin down to 13.6% from 14.1%. Official statements.

Administrative expense is another line to watch. Q2 administrative cost increased about 40.8% to Rs675.8 million, and the H1 increase was 23.6% to Rs1.258 billion. The company does not provide a specific explanation for the increase in the interim report, so it should not be treated as either recurring or exceptional without further disclosure. If this cost base keeps rising, some of the benefit from gross-margin expansion could be diluted. Official statements.

Q2 sales also fell 1.6% year on year and were about 14.9% below Q1 2026. Sequential comparisons can be affected by seasonality and tender timing, so the quarter-on-quarter decline should not be overinterpreted. Still, it means the June quarter’s margin improvement came despite a softer sales base, and the next result needs to show whether revenue growth reaccelerates. Q2 and Q1 reports.

What actually drove H1 growth

Management reports H1 net sales of Rs31.5 billion, including Rs0.49 billion of sales to Haleon Pakistan versus Rs0.57 billion a year earlier. Excluding those Haleon sales, management calculates underlying sales growth at 4.4% and says the increase was mainly driven by price increases and tender business. This distinction matters because the company’s legacy OTC manufacturing relationship with Haleon is gradually changing as marketing authorisations and permissions transfer. Directors’ review.

The Haleon transition is visible in the notes. GSK had been procuring, manufacturing and managing inventory and receivables for certain OTC products on Haleon’s behalf while regulatory transfers were pending. Some marketing authorisations have now transferred, after which Haleon takes responsibility for procurement, manufacturing and related inventory. That means the Haleon-linked sales line can shrink without necessarily indicating deterioration in GSK’s core portfolio. Note 1.1 and revenue note.

Recurring versus non-recurring earnings

The best recurring signal is the gross-to-operating profit progression. H1 gross profit increased by about Rs1.22 billion and operating profit by about Rs0.73 billion. Those gains are larger and more economically meaningful than movements in non-core income. The company’s stated drivers—pricing, tender business, operational efficiency and cost optimisation—are operating factors, even though their sustainability still needs to be tested. Official statements and directors’ review.

Other income was not a major earnings accelerator. H1 other income declined slightly to Rs713 million from Rs745 million. Within that total, income on savings and deposits increased to Rs360 million from Rs205 million, while promotional allowance from the GSK group fell materially. Q2 other income was nearly flat year on year. The result therefore is not dependent on a large one-off gain. Other-income note.

The tax line deserves special treatment. The notes discuss the super-tax litigation and state that in January 2026 the Federal Constitutional Court upheld the validity of Section 4C, after which the company paid outstanding super-tax liabilities, including amounts relating to FY2021 and FY2022. The report does not isolate how much of the current-period tax charge is directly attributable to that development, so the exact Q2 tax increase should not be labelled as a one-off. What can be said safely is that tax absorbed a larger share of pre-tax earnings this quarter. Taxation note.

Cash flow: good operating generation, but taxes and inventory absorb cash

Cash generated from operations before taxes and certain payments improved strongly to Rs8.664 billion from Rs6.987 billion. Net operating cash flow, however, rose only modestly to Rs3.880 billion from Rs3.763 billion because income taxes paid increased to Rs4.422 billion from Rs3.146 billion and retirement-benefit contributions were also higher. Official cash flow.

Working capital explains another important part of the cash story. Stock-in-trade absorbed Rs2.807 billion of cash during H1, though that was less than the Rs3.714 billion outflow in the comparable period. Loans and advances absorbed another Rs1.095 billion. These uses were partly offset by a Rs1.829 billion release from other receivables and a Rs2.157 billion increase in trade and other payables. Cash generated from operations note.

After Rs737.5 million of capital expenditure, operating cash flow less capex was roughly Rs3.14 billion, compared with about Rs2.83 billion in H1 2025. This is an analytical subtotal rather than a company-reported free-cash-flow measure. Dividends paid of Rs3.796 billion meant period-end cash stayed broadly flat at Rs8.426 billion versus Rs8.592 billion at December 2025. Official cash flow.

Balance sheet: liquid, lightly financed, but inventory has risen

GSK remained financially conservative at June 30. Current assets were Rs37.143 billion against current liabilities of Rs16.287 billion, giving a current ratio of about 2.28 times. Cash and bank balances were Rs8.426 billion. There is no separate bank-borrowing line in the statement of financial position; lease liabilities totalled only about Rs353 million across current and non-current portions. Official balance sheet.

The main balance-sheet movement is inventory. Stock-in-trade increased to Rs15.416 billion from Rs12.774 billion at December 2025, a 20.7% rise. Finished goods alone increased to Rs8.431 billion before provisions from Rs6.733 billion. Inventory growth can support future availability and tender fulfilment, but it also ties up cash and raises execution risk if demand is weaker than planned. The next quarter should therefore show whether this build converts into revenue rather than remaining on the balance sheet. Stock-in-trade note.

Trade receivables declined 4.7% from December to Rs2.679 billion, while trade and other payables increased 15.3% to Rs15.836 billion. Current liabilities therefore rose somewhat faster than current assets, causing the current ratio to ease from about 2.32 times to 2.28 times, though liquidity remains comfortable. Official balance sheet.

Sector and regulatory context

Pakistan’s manufacturing environment was mixed around the reporting period. PBS reported overall large-scale manufacturing growth of 4.98% for July-June FY2026, but June output itself was down 3.48% year on year and 6.08% month on month. This does not directly measure pharmaceutical demand, but it reinforces that GSK’s profitability improvement occurred against a macro backdrop that was recovering unevenly rather than uniformly strong. PBS June 2026 LSM release.

The pharmaceutical sector remains heavily shaped by regulation. DRAP’s pricing framework and the 2024 deregulation of non-essential medicines have improved pricing flexibility for eligible products, while essential medicines remain more constrained. GSK explicitly says it is still engaging authorities on hardship cases for certain essential medicines and pricing-threshold matters for non-essential products. Margin sustainability therefore depends not only on commercial execution but also on how regulation evolves. DRAP pricing-policy background. GSK directors’ review.

Peer data underline that GSK’s Q2 top-line softness was not simply an industry-wide collapse. Abbott Laboratories Pakistan reported Q2 2026 sales of about Rs20.32 billion versus Rs19.06 billion a year earlier and PAT of about Rs2.20 billion versus Rs1.94 billion. The comparison is not like-for-like because product portfolios differ, but it suggests company mix, tender timing and portfolio-specific factors matter materially. Abbott PSX profile and Q2 filing history.

Dividend and capital allocation

The Board approved an interim dividend of Rs7 per share, amounting to about Rs2.229 billion, compared with Rs5 per share for the corresponding prior-year period. The higher distribution sits alongside stronger H1 earnings and a liquid balance sheet. Cash dividends actually paid during H1 were Rs3.796 billion, reflecting the timing of declared distributions including the prior final dividend. Subsequent-events note and cash flow.

Capital expenditure was Rs737.5 million in H1, down from Rs934.7 million. The company still had Rs500 million of capital commitments at June 30. This leaves room for continued maintenance and productivity investment without creating obvious balance-sheet strain, but investors should watch whether inventory and working-capital needs compete with dividends and reinvestment for cash. Cash flow and commitments note.

What to monitor next

  • Revenue reacceleration: Q2 sales declined year on year and sequentially. The next result should show whether tender timing and core portfolio growth restore top-line momentum.
  • Gross-margin durability: H1 gross margin improved by about 2.5 percentage points. The key test is whether deregulation-linked pricing and cost optimisation can hold margins near the high-30s.
  • Tax burden: Q2’s effective tax rate was materially higher. Future disclosures should clarify whether the tax intensity normalises or remains a structural drag.
  • Inventory conversion: the 20.7% increase in stock-in-trade needs to translate into sales and cash rather than further working-capital absorption.
  • Administrative costs: the sharp increase in Q2 and H1 should be monitored for recurrence.
  • Regulatory pricing: progress on essential-drug hardship cases and non-essential pricing thresholds can affect product economics.
  • Haleon transition: shrinking OTC manufacturing sales to Haleon should be separated from the underlying GSK portfolio so headline revenue comparisons are interpreted correctly.
  • Cash returns: with an Rs7 interim dividend and continued capex, the balance between shareholder distributions, inventory funding and reinvestment remains important.

Bottom line

GSK Pakistan’s H1 2026 result is stronger than the Q2 PAT decline alone suggests. The June quarter delivered better gross and operating margins despite slightly lower revenue, while the half year produced double-digit growth in gross profit, operating profit and pre-tax earnings. Management’s explanation—pricing, tenders, deregulation and cost measures—is supported by the public regulatory backdrop and by the financial statements. Official H1 2026 report.

The pressure points are equally clear. Tax consumed more of Q2 pre-tax profit, administrative costs rose sharply and inventory expanded by more than 20% from December. The balance sheet is still liquid and lightly financed, and operating cash generation remains solid, but the next cycle needs to convert inventory into revenue and demonstrate that the margin gains can persist without relying on further price increases. That, more than a single quarter’s PAT movement, will determine whether the current improvement represents a durable step-up in the business.

Sources

Explore more research

All articles